An iron-binding drug that is already approved for treatment of other diseases could provide a novel way to attack ovarian tumors, according to a new study led by Weill Cornell Medicine researchers.

This perspective argues that Parkinson’s disease may involve functional iron deficiency, where bioavailable iron is limited despite normal or elevated total iron in the brain. The authors propose that ...